Assembly biosciences to highlight pipeline progress in hbv and hdv at the 2023 international hbv meeting

-- two oral presentations and one poster will feature new data from the company's hepatitis b/hepatitis d entry inhibitor, capsid assembly modulator abi-4334, and interferon-alpha receptor agonist programs -- south san francisco, calif., sept. 19, 2023 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that the company will present new preclinical data from multiple hepatitis b virus (hbv) and hepatitis d virus (hdv) pipeline programs at the 2023 international hbv meeting taking place in kobe, japan, september 19-23, 2023.
ASMB Ratings Summary
ASMB Quant Ranking